La catena delle opzioni mostra i dati chiave delle opzioni azionarie di Annovis Bio a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per Annovis Bio..

Annovis Bio (NYSE:ANVS) Azioni, Catena delle Opzioni

Annovis Bio

Annovis Bio Inc is a clinical-stage pharmaceutical company focused on developing and commercializing drugs for the treatment of Parkinson's and Alzheimer's diseases and other neurodegenerative diseases. The pipeline products of the company consists of: Buntanetap for chronic neurodegeneration - including AD and PD; ANVS405 for acute neurodegeneration; and ANVS301 for advanced AD.

Annovis Bio Inc

Warning: ANVS is at high risk of performing badly

As previously reported, Maxim upgraded Annovis Bio (ANVS) to Buy from Hold with a $25 price target The company has recently provided an update on i...

Annovis Bio upgraded to Buy at Maxim following buntanetap update

The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need...

Apple downgraded, Tesla upgraded: Wall Street's top analyst calls

AAPL

ANVS

APLS

BLDR

BYON

DENN

TMUS

TSLA

UBER

Health Care

Press Releases

Annovis Bio Reports Second Quarter Financial Results and Provides Business Update

News

Annovis Bio (NYSE: ANVS) to Present at H.C. Wainwright 26th Annual Global Investment Conference

Legal

Annovis Files Three New Patents for Combination Therapies Involving  Buntanetap, Trulicity, and Viagra

Opinion

Transforming Alzheimer's Treatment: Innovative Combinations to Boost Cognition

General

Annovis Bio Inc. (NYSE: ANVS) Research Points to Potential Future Breakthroughs in AD Space Through Innovative Combinations

Annovis Bio Inc. (NYSE: ANVS) Leading Way in Development of Safe, Effective Drugs for Neurodegenerative Diseases

Small Cap

Beyond the Horizon: Innovative Drug Combinations Offer New Hope for Alzheimer's and More

FDA Clears Annovis to Launch Pivotal Phase 3 Alzheimer's Studies, Paving the Way to NDAs

Annovis to Highlight Buntanetap's Alzheimer's Research Progress with Presentations at CTAD 2024

IBN Announces Latest Episode of The BioMedWire Podcast Featuring Dr. Maria Maccecchini, CEO of Annovis Bio

ABBV

Adicet Bio

Adagene Inc. - ADS, each representing 1.25 ordinary shares

Adagene

Allakos

AlloVir

Anixa Biosciences

Assembly Biosciences, Inc. - Common Stock

Assembly Biosciences

Cibus

Coya Therapeutics

CervoMed

Elutia

FibroBiologics

Genelux

Immunic

INmune Bio

Inovio Pharmaceuticals, Inc. - Common Stock

Inovio Pharmaceuticals

Century Therapeutics, Inc. - Common Stock

Century Therapeutics

Invivyd

Karyopharm Therapeutics Inc. - Common Stock

Karyopharm Therapeutics

Leap Therapeutics

Seres Therapeutics

Nuvectis Pharma

Puma Biotechnology

PDS Biotechnology Corporation - Common Stock

PDS Biotechnology

Qualigen Therapeutics, Inc. - Common Stock

Qualigen Therapeutics

TriSalus Life Sciences, Inc. - Common Stock

TriSalus Life Sciences

Maxim Group

HC Wainwright & Co.

EF Hutton

Rodman & Renshaw

Comments

Annovis Bio

Annovis Bio (ANVS) Opzioni

Annovis Bio (NYSE:ANVS) Azioni, Catena delle Opzioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO